The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics
Authors:
- William TillettWTWilliam Tillett
- David ChandlerDCDavid Chandler
- Philip S. HelliwellPHPhilip S. Helliwell
- Eleanor KorendowychEKEleanor Korendowych
- Stuart KyleSKStuart Kyle
- Iain B. McInnesIMIain B. McInnes
- Susan OliverSOSusan Oliver
- Anthony OrmerodAOAnthony Ormerod
- Catherine SmithCSCatherine Smith
- Deborah SymmonsDSDeborah Symmons
- Nicola WaldronNWNicola Waldron
Open Access
- 23 July 2013
- journal article
- practice guideline
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 52 (10) , 1754-1757
Abstract
PsA is a chronic inflammatory arthropathy affecting up to 40% of patients with skin or nail psoriasis. It is considered a type of seronegative spondyloarthritis and can cause arthritis, enthesitis, dactylitis and axial inflammation. The use of anti-TNF therapy for the treatment of inflammatory arthritis, including PsA, has revolutionized therapeutic options in rheumatology.Keywords
This publication has 2 references indexed in Scilit:
- 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisAnnals of the Rheumatic Diseases, 2011
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009